STRS Ohio’s Corvus Pharmaceuticals CRVS Stock Holding History

STRS Ohio’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,100	Closed	-$12K	–	2128
2018 Q1	$12K	Hold	1,100	–	–	﹤0.01%	1835
2017 Q4	$11K	Hold	1,100	–	–	﹤0.01%	1844
2017 Q3	$17K	Hold	1,100	–	–	﹤0.01%	1874
2017 Q2	$13K	Hold	1,100	–	–	﹤0.01%	1892
2017 Q1	$22K	Hold	1,100	–	–	﹤0.01%	1827
2016 Q4	$15K	Hold	1,100	–	–	﹤0.01%	1868
2016 Q3	$18K	Hold	1,100	–	–	﹤0.01%	1847
2016 Q2	$15K	Buy	+1,100	New	+$14.9K	﹤0.01%	1873

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

STRS Ohio's CRVS Position: Q2 2018 in Review

STRS Ohio sold out of Corvus Pharmaceuticals (CRVS) in Q2 2018, closing a stake of 1,100 shares — an estimated $12K sold.

STRS Ohio first reported a position in CRVS in Q2 2016 and held it in 8 quarters. The position peaked at $22K in Q1 2017. 57 funds tracked by Wall St. Rank hold CRVS as of Q2 2018.

STRS Ohio reported no remaining Corvus Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
STRS Ohio sold 1,100 Corvus Pharmaceuticals shares in Q2 2018, an estimated $12K.
STRS Ohio first reported a position in Corvus Pharmaceuticals in Q2 2016 and held it in 8 quarters.
STRS Ohio's Corvus Pharmaceuticals position peaked at $22K in Q1 2017.
57 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2018.

Based on STRS Ohio's 13F filing for Q2 2018, filed 6 Aug 2018.